Navigation Links
FRC's Jeanne Monahan Responds to Two New Deaths from RU-486
Date:10/1/2010

WASHINGTON, Oct. 1 /PRNewswire-USNewswire/ -- U.S. Centers for Disease Control and Prevention officials have disclosed that two mifepristone (RU-486)-induced deaths occurred in the past two years, bringing the total number of reported death related to RU-486 to 12. This announcement comes almost 10 years to the date after the Food and Drug Administration (FDA) approved the abortion drug, deeming it a major advancement for women's health and safe for public use.

(Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO)

The news came in a letter to the editor of the New England Journal of Medicine on September 30, 2010. Both mifepristone-induced septic shock deaths were caused by c. sordellii, the bacteria linked to a number of RU-486 deaths from 2000-2006.

One woman who died was 29; the other was 21. The deaths occurred in 2008 and 2009, respectively. The public is only now learning of these deaths.

Of this announcement, Family Research Council's Director of the Center for Human Dignity Jeanne Monahan, who formerly worked in the Office of the Secretary in the Department of Health and Human Services, made the following comments:

"Abortion proponents claim that abortions should be 'safe, legal and rare.' Yet RU-486 use is increasing and its safety record is entirely dubious, as these two deaths prove.

"Ten years ago, the FDA's approval process for RU-486 was flawed, relying primarily on French data that the FDA admitted was marked by 'carelessness,' 'fraud,' and 'evidence tampering.' And while the abortion industry achieved a major victory with the approval of RU-486, women have been the victims of the abortion agenda.

"Other drugs with less extreme adverse affects have been pulled from the market quickly, but not RU-486, whose over 1,300 adverse affects on women using the drug – including 336 hospitalizations, 172 blood transfusions, and most gravely, 12 deaths – have been ignored. These two women are just the latest of many to pay a severe price.

"Ten years later, the FDA approved ulipristal acetate – 'ella' – as an emergency contraceptive, despite the fact that it shares an almost identical chemical make-up and identical modes of action with RU-486. Given the strong resemblance, there is reason to believe that the negative side effects will also be similar. Women should not be the 'guinea pigs' of the abortion industry or the government. These risks should not be taken," Monahan concluded.

For more information on RU-486:

FRC Senior Fellow Chris Gacek on the FDA's approval of RU-486: http://www.frc.org/content/politicized-science-the-manipulated-approval-of-ru-486-and-its-dangers-to-womens-health

Jeanne Monahan in Human Events regarding the tenth anniversary of RU-486: http://www.humanevents.com/article.php?id=39179


'/>"/>
SOURCE Family Research Council
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
2. Atrium Responds to Bard Suit
3. NVHR Responds to New York Times Article on Hepatitis C Testing
4. Takeda Responds to FDA Advisory Committee Recommendation
5. Coalition for Pulmonary Fibrosis Responds to News of Further Review of Pirfenidone By FDA
6. New Science Education Program Responds to Presidents Call to Help Young People Excel in Science
7. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
8. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
9. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
10. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
11. Endologix Responds to Alleged Patent Infringement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Yissum Research Development ... today that it had signed an exclusive world-wide licensing ... of novel protein degradation and immunomodulatory drugs for cancer ... drug candidates representing first-in-class therapy for hematologic and solid ... The novel technology was developed by ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... A local ... that more than 40 percent of participating fifth-grade students already have or are ... and Asthma Clinical Research in the Division of Pulmonary, Allergy and Critical Care ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... , ... May 05, 2016 , ... The 2016 Nike ... Derek Pittman, along with his university coaching staff. Together they bring their winning Vandals ... sessions run for youth players ages 5-13, and high school players. Session dates are ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy ... alleviate the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies ... with arthritis. , “Physical therapy exercises are commonly prescribed to individuals with ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Lung Institute will celebrate its three-year ... seminar at most clinic locations throughout the month of May. To date, the Lung Institute ... rapid growth that we’ve seen is a testament to the success of this treatment and ...
Breaking Medicine News(10 mins):